Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 237

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 237
---
 company private due to challenging market conditions as well as a desire to avoid the convertible structure route.

<div align='center'>110</div>

TABLE OF CONTENTS

Target F (Liminatus): On October 25, 2022, Liminatus was brought to Iris by Cantor Fitzgerald as a potential business combination target. Following a preliminary assessment, Iris decided to initiate discussions with Liminatus.

On October 29, 2022, Iris had an introductory call with Liminatus to obtain an understanding of Liminatus, its history, business model, products and the leadership. Iris also introduced itself and its purpose to Liminatus.

On October 30, 2022, Iris and Liminatus executed a non-disclosure agreement and Liminatus granted Iris data room access to commence due diligence.

On November 1, 2022, following an initial assessment of the data room (by Iris and certain of its advisors), Iris and Liminatus executed a letter of intent (as amended, the “Business Combination LOI”).

On November 2, 2022, an all-party call was held among Liminatus, Iris and their respective legal teams. The primary purposes of this call were to introduce the advisors and discuss next steps. Iris engaged third party subject matter experts to support and advise Iris management on assessing Liminatus as a potential target for a business combination, including experts to conduct due diligence on Liminatus’s intellectual property portfolio and regulatory and scientific matters related to Liminatus.

On November 3, 2022, Iris management met with the Iris Board to brief the Iris Board about Liminatus, potential deal terms and preliminary sector analysis.

On November 5, 2022, Iris and Liminatus had detailed discussions and exchanged draft versions of certain ancillary agreements related to the business combination.

On November 7, 2022, Iris received certain reports containing preliminary due diligence findings by its advisors. Additionally, Iris initiated the process to extend the timeline to complete a business combination and commenced work on the preliminary proxy statement related to such extension.

On November 8, 2022, an all-party call was conducted among Iris, Liminatus and their respective legal teams to discuss on-going due diligence.

From November 10 through November 14, 2022, Iris, Liminatus, and their respective advisors exchanged due diligence queries and responses. From November 15 through November 19, 2022, Iris received additional due diligence reports from its advisors and subsequently